FDA Brief

Warning letters Drugs

FDA warning letter to

Ivermectin24h.com

High riskIssued Feb 25, 2022Posted Mar 15, 2022Center for Drug Evaluation and Research | CDER

FDA warned Ivermectin24h.com for selling hydroxychloroquine online without prescriptions and claiming it treats COVID-19.

What happened

FDA reviewed the website www.ivermectin24h.com on December 13, 2021. FDA found the homepage asked “Worried about CORONAVIRUS?” and a “BUY NOW” button led to a page selling “Hydroxychloroquine,” which the site said treats malaria, lupus, and rheumatoid arthritis. FDA said the site offered this prescription drug without requiring a prescription and made claims about uses for which FDA has not approved it, including COVID-19.

What FDA found

  1. The website offers hydroxychloroquine, a prescription drug, without requiring a prescription, so the drug is misbranded.

    section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]
  2. The website claims hydroxychloroquine can treat COVID-19 even though FDA has not approved it for that use.

    section 503(b) of the FD&C Act [21 U.S.C. § 353(b)]
  3. Offering the misbranded drug for sale to U.S. consumers causes it to be introduced into interstate commerce.

    section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]
  4. Dispensing a prescription drug without a prescription results in the drug being misbranded while held for sale.

    section 301(k) of the FD&C Act [21 U.S.C. § 331(k)]

What FDA wants

Within 48 hours, FDA asks the company to email FDA describing the specific steps taken to address the violations and prevent recurrence. If corrective action cannot be completed within 48 hours, the company must state the reason for delay and when it will complete the corrections.

Who should pay attention

  • online pharmacies selling prescription drugs
  • consumers seeking COVID-19 treatments online
  • companies making unapproved drug claims on websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk